Thus, the GEOMETRY mono-1 trial evaluated MET-dysregulated, advanced NSCLC, with promising ORR and PFS seen in MET exon 14 skip mutations, though the results showed a lack of effect in MET GCN < 10, leading to FDA and EMA approval for capmatinib only in advanced NSCLC with MET exon 14 skipping mutations. This evidence concerns the gene MET and non-small cell lung carcinoma.